Hepatitis C News and Research

Latest Hepatitis C News and Research

Dropping of cold chain requirement for meningitis vaccine will improve access, IRIN reports

IRIN examines how the WHO's recent declaration that the MenAfriVac meningitis A vaccine can be transported or stored for up to four days without refrigeration will affect immunization campaigns in Africa's meningitis belt, which runs from Senegal to Ethiopia.

22 Nov 2012

Promising results for pneumococcal vaccine

Research published in The Lancet shows that the PHiD-CV10 vaccine is highly effective at protecting children against invasive pneumococcal disease.

21 Nov 2012

GSK receives FDA approval for PROMACTA to treat thrombocytopenia

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved PROMACTA for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy.

19 Nov 2012

HCV medications' side effects can now be replicated and observed in Petri dishes and test tubes

The adverse side effects of certain hepatitis C medications can now be replicated and observed in Petri dishes and test tubes, thanks to a research team led by Craig Cameron, the Paul Berg Professor of Biochemistry and Molecular Biology at Penn State University.

17 Nov 2012

New pneumococcal vaccine highly effective in infants

A new conjugate vaccine is highly effective (93–100%) at preventing invasive pneumococcal disease (IPD; meningitis, sepsis, bacteremic pneumonia, and other blood-borne infections) in infants younger than 2 years who are the most vulnerable to infection, according to new research published Online First in The Lancet.

16 Nov 2012

ALN RNAi therapeutic program represents novel approach for treatment of AAT deficiency

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with an RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of liver disease associated with AAT deficiency. These data were presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD, "The Liver Meeting") held November 9-13, 2012 in Boston.

15 Nov 2012

Ligand Pharmaceuticals announces data from LG-7501 preclinical studies on HCV

Ligand Pharmaceuticals Incorporated announced that data from preclinical studies evaluating LG-7501 were featured in a poster presentation today at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases in Boston.

14 Nov 2012

Abbott releases details on phase 3 hepatitis C registrational program

Abbott today released details on its phase 3 hepatitis C registrational program following promising results from its phase 2b clinical trial, known as Aviator, presented at the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) in Boston.

13 Nov 2012

Weight-based ribavirin undertreats African–American HCV patients

African–Americans with hepatitis C virus genotype 1 infections have lower ribavirin plasma exposures than Caucasian Americans when treated with weight-based ribavirin plus peginterferon.

12 Nov 2012

BioCryst completes planned interim analysis of peramivir Phase 3 trial for serious influenza

BioCryst Pharmaceuticals, Inc. announced completion of the planned interim analysis of the peramivir Phase 3 trial in patients admitted to the hospital with serious influenza. The difference between peramivir and control groups for the primary endpoint was small and the recalculated sample size was greater than the predefined futility boundary of 320 subjects. Based on this information, the independent data monitoring committee (DMC) recommended that the study be terminated for futility.

8 Nov 2012

EPO provides notice of intent to issue European Patent Application for Aethlon Hemopurifier

Aethlon Medical, Inc., the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that the European Patent Office (EPO) has provided the Company a notice of intent to issue European Patent Application No. 04 703 672.8 entitled "Method For Removal of Viruses From Blood By Lectin Affinity Hemodialysis."

7 Nov 2012

SCYNEXIS announces results from SCY-635 Phase 2a study on HCV

SCYNEXIS, Inc. today announced that the results of a Phase 2a study of lead candidate SCY-635 for the treatment of the hepatitis C virus (HCV) will be the subject of an oral presentation at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place from November 9-13 in Boston, Massachusetts.

7 Nov 2012

Inhibition of NOX4 enzyme plays an important role in liver fibrosis

Researchers at the Bellvitge Biomedical Research Institute (IDIBELL) have led a study published in PLoS One showing that the inhibition of a family member of NADPH oxidase enzyme, NOX4, plays an important role in liver fibrosis.

5 Nov 2012

State highlights: N.H. hospital in Hepatitis outbreak must allow access to patient records

A New Hampshire judge says a hospital tied to a hepatitis C outbreak must grant public health officials broad access to patient records. Exeter Hospital had argued it would be violating state and federal law if it provided unfettered access to its records system. But a Merrimack County Superior Court judge on Thursday sided with the state.

3 Nov 2012

Phase II study to evaluate Medivir/Janssen's simeprevir and Vertex against HCV

Medivir AB, announced today plans for a phase II proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing of Medivir/Janssen's protease inhibitor simeprevir and Vertex's nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor VX-135.

3 Nov 2012

Janssen, Vertex to evaluate TMC435 and VX-135 in Phase 2 HCV study

Janssen Pharmaceuticals, Inc. today announced that it has entered into a non-exclusive collaboration with Vertex Pharmaceuticals Incorporated to evaluate in a Phase 2 study the safety and efficacy of an all-oral regimen for the treatment of hepatitis C (HCV).

2 Nov 2012

Study shows reduced risk of liver-related mortality in African American women with HIV/HCV

A new study shows that African American women coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are less likely to die from liver disease than Caucasian or Hispanic women. Findings in the November issue of Hepatology, a journal published by Wiley on behalf of the American Association for the Study of Liver Diseases, indicate that lower liver-related mortality in African American women was independent of other causes of death.

1 Nov 2012

African American women coinfected with HIV and HCV less likely to die from liver disease than Caucasian or Hispanic women

31 Oct 2012

BioCryst announces withdrawal of BCX5191 IND following discussion with FDA

BioCryst Pharmaceuticals, Inc. announced the withdrawal of its Investigational New Drug application (IND) for the antiviral nucleoside, BCX5191, following a discussion with the U.S. Food and Drug Administration (FDA).

31 Oct 2012

Allergies and hygiene: an interview with Sally Bloomfield

Allergies occur when the body overreacts to substances in our environment, such as pollen, dust mites and so forth. What happens is that when we are exposed to these potential threats, the immune system should react, deal with it, and then shut down.

26 Oct 2012

Hepatitis C News and Research

Latest Hepatitis C News and Research

Dropping of cold chain requirement for meningitis vaccine will improve access, IRIN reports

Promising results for pneumococcal vaccine

GSK receives FDA approval for PROMACTA to treat thrombocytopenia

HCV medications' side effects can now be replicated and observed in Petri dishes and test tubes

New pneumococcal vaccine highly effective in infants

ALN RNAi therapeutic program represents novel approach for treatment of AAT deficiency

Ligand Pharmaceuticals announces data from LG-7501 preclinical studies on HCV

Abbott releases details on phase 3 hepatitis C registrational program

Weight-based ribavirin undertreats African–American HCV patients

BioCryst completes planned interim analysis of peramivir Phase 3 trial for serious influenza

EPO provides notice of intent to issue European Patent Application for Aethlon Hemopurifier

SCYNEXIS announces results from SCY-635 Phase 2a study on HCV

Inhibition of NOX4 enzyme plays an important role in liver fibrosis

State highlights: N.H. hospital in Hepatitis outbreak must allow access to patient records

Phase II study to evaluate Medivir/Janssen's simeprevir and Vertex against HCV

Janssen, Vertex to evaluate TMC435 and VX-135 in Phase 2 HCV study

Study shows reduced risk of liver-related mortality in African American women with HIV/HCV

African American women coinfected with HIV and HCV less likely to die from liver disease than Caucasian or Hispanic women

BioCryst announces withdrawal of BCX5191 IND following discussion with FDA

Allergies and hygiene: an interview with Sally Bloomfield

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Hepatitis C News and Research

Latest Hepatitis C News and Research

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in